Wissenschaftliche Publikationen Suche Suche Autor/in Forschungsgruppe Veröffentlichungsdatum Suchen Sortieren nach RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Reihenfolge AufsteigendAbsteigend Hinz, Michael Dr. (2) Scheidereit, Claus Prof. Dr. (3) Wollert-Wulf, Brigitte (1) (-) Janz, Martin Dr. (2) (-) Mathas, Stephan Dr. (11) (-) Biologie maligner Lymphome (11) Molekulare Immunologie und Gentherapie (16) Systembiologie von Gen-regulatorischen Elementen (1) 1999 (1) (-) 2000 (1) 2001 (1) (-) 2002 (5) 2003 (3) 2004 (3) 2005 (3) 2006 (5) 2007 (4) 2008 (4) 2009 (4) 2010 (3) 2011 (4) 2012 (2) 2013 (3) 2014 (2) (-) 2015 (5) 2016 (3) 2017 (5) 2018 (1) 2019 (2) 2020 (6) 2021 (3) 2022 (7) 2023 (10) 2024 (2) 11 Ergebnisse: Active Filter: Janz, Martin Dr.Mathas, Stephan Dr.Biologie maligner Lymphome200020022015 Sortieren: Treffgenauigkeit Neueste nach älteste Älteste nach neueste 01. Mai 2002 / Blood Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma F. Jundt I. Anagnostopoulos R. Foerster S. Mathas H. Stein B. Doerken 01. November 2002 / Blood In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp 130/STAT3 pathway M. Chatterjee D. Hoenemann S. Lentzsch K. Bommert C. Sers P. Herrmann S. Mathas B. Doerken R.C. Bargou 02. September 2002 / J Exp Med Nuclear factor κB-dependent gene expression profiling of Hodgkins disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity M. Hinz P. Lemke I. Anagnostopoulos C. Hacker D. Krappmann S. Mathas B. Doerken M. Zenke H. Stein C. Scheidereit 01. Januar 2000 / Canc Res Anti-CD20-and B-cell receptor-mediated apoptosis: Evidence for shared intracellular signaling pathways S. Mathas A. Rickers K. Bommert B. Doerken M.Y. Mapara 01. August 2002 / EMBO J Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B S. Mathas M. Hinz L. Anagnostopoulos D. Krappmann A. Lietz F. Jundt K. Bommert F. Mechta-Grigoriou H. Stein B. Dörken C. Scheidereit 15. April 2002 / Blood Loss of PU.1 expression is associated with defective immunoglobulin transcription in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease F. Jundt K. Kley I. Anagnostopoulos K. Schulze-Proebsting A. Greiner S. Mathas C. Scheidereit T. Wirth H. Stein B. Doerken 01. Mai 2015 / Leukemia The IL-15 cytokine system provides growth and survival signals in hodgkin lymphoma and enhances the inflammatory phenotype of HRS cells K. Ullrich F. Blumenthal-Barby B. Lamprecht K. Koechert D. Lenze M. Hummel S. Mathas B. Doerken M. Janz 01. März 2015 / Cytokine Cytokine and proinflammatory gene expression in classical Hodgkin lymphoma: its more than NF-κB! S. Kreher P. Cauchy C. Bonifer S. Mathas 01. Januar 2015 / Blood Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma A. Weilemann M. Grau T. Erdmann O. Merkel U. Sobhiafshar I. Anagnostopoulos M. Hummel A. Siegert C. Hayford H. Madle B. Wollert-Wulf I. Fichtner B. Dörken S. Dirnhofer S. Mathas M. Janz N.C.T. Emre A. Rosenwald G. Ott P. Lenz A. Tzankov G. Lenz 11. April 2015 / Lancet Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial K. Behringer H. Goergen F. Hitz J.M. Zijlstra R. Greil J. Markova S. Sasse M. Fuchs M.S. Topp M. Soekler S. Mathas J. Meissner M. Wilhelm P. Koch H.W. Lindemann E. Schalk R. Semrau J. Kriz T. Vieler M. Bentz E. Lange R. Mahlberg A. Hassler M. Vogelhuber D. Hahn J. Mezger S.W. Krause N. Skoetz B. Böll B. von Tresckow V. Diehl M. Hallek P. Borchmann H. Stein H. Eich A. Engert Seitennummerierung Aktuelle Seite 1 Seite 2 Nächste Seite Next › Letzte Seite Last »
01. Mai 2002 / Blood Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma F. Jundt I. Anagnostopoulos R. Foerster S. Mathas H. Stein B. Doerken
01. November 2002 / Blood In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp 130/STAT3 pathway M. Chatterjee D. Hoenemann S. Lentzsch K. Bommert C. Sers P. Herrmann S. Mathas B. Doerken R.C. Bargou
02. September 2002 / J Exp Med Nuclear factor κB-dependent gene expression profiling of Hodgkins disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity M. Hinz P. Lemke I. Anagnostopoulos C. Hacker D. Krappmann S. Mathas B. Doerken M. Zenke H. Stein C. Scheidereit
01. Januar 2000 / Canc Res Anti-CD20-and B-cell receptor-mediated apoptosis: Evidence for shared intracellular signaling pathways S. Mathas A. Rickers K. Bommert B. Doerken M.Y. Mapara
01. August 2002 / EMBO J Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B S. Mathas M. Hinz L. Anagnostopoulos D. Krappmann A. Lietz F. Jundt K. Bommert F. Mechta-Grigoriou H. Stein B. Dörken C. Scheidereit
15. April 2002 / Blood Loss of PU.1 expression is associated with defective immunoglobulin transcription in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease F. Jundt K. Kley I. Anagnostopoulos K. Schulze-Proebsting A. Greiner S. Mathas C. Scheidereit T. Wirth H. Stein B. Doerken
01. Mai 2015 / Leukemia The IL-15 cytokine system provides growth and survival signals in hodgkin lymphoma and enhances the inflammatory phenotype of HRS cells K. Ullrich F. Blumenthal-Barby B. Lamprecht K. Koechert D. Lenze M. Hummel S. Mathas B. Doerken M. Janz
01. März 2015 / Cytokine Cytokine and proinflammatory gene expression in classical Hodgkin lymphoma: its more than NF-κB! S. Kreher P. Cauchy C. Bonifer S. Mathas
01. Januar 2015 / Blood Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma A. Weilemann M. Grau T. Erdmann O. Merkel U. Sobhiafshar I. Anagnostopoulos M. Hummel A. Siegert C. Hayford H. Madle B. Wollert-Wulf I. Fichtner B. Dörken S. Dirnhofer S. Mathas M. Janz N.C.T. Emre A. Rosenwald G. Ott P. Lenz A. Tzankov G. Lenz
11. April 2015 / Lancet Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial K. Behringer H. Goergen F. Hitz J.M. Zijlstra R. Greil J. Markova S. Sasse M. Fuchs M.S. Topp M. Soekler S. Mathas J. Meissner M. Wilhelm P. Koch H.W. Lindemann E. Schalk R. Semrau J. Kriz T. Vieler M. Bentz E. Lange R. Mahlberg A. Hassler M. Vogelhuber D. Hahn J. Mezger S.W. Krause N. Skoetz B. Böll B. von Tresckow V. Diehl M. Hallek P. Borchmann H. Stein H. Eich A. Engert